Patents by Inventor Mitsunori Ono
Mitsunori Ono has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110039927Abstract: The invention relates to compositions and processes for producing novel hop acid formulations having improved bioavailability, and the use of such compositions as anti-inflammatory agents, dietary supplements, and pharmaceuticals.Type: ApplicationFiled: June 21, 2006Publication date: February 17, 2011Inventors: Kevin K. Madsen, Mark M. Bossert, Mitsunori Ono
-
Patent number: 7833552Abstract: A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for treating various diseases, e.g., skin disorders, and bacterial infection.Type: GrantFiled: August 13, 2008Date of Patent: November 16, 2010Assignee: Flaxan GmbH & Co. KGInventors: Mitsunori Ono, Naoto Yamaguchi
-
Publication number: 20100280075Abstract: Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and Rg are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and Rg is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ?O or ?S.Type: ApplicationFiled: January 25, 2010Publication date: November 4, 2010Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono
-
Patent number: 7763658Abstract: One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group, or, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Preferably R1 and R2 are the same and R3 and R4 are the same. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.Type: GrantFiled: January 15, 2004Date of Patent: July 27, 2010Assignee: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Yaming Wu, Timothy Korbut, Dan Zhou, Zhenjian Du, Shoujun Chen, Noriaki Tatsuta, Guiqing Liang, Mitsunori Ono
-
Publication number: 20100173413Abstract: This invention features compounds of formula (I): pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12-related diseases and disorders.Type: ApplicationFiled: March 11, 2010Publication date: July 8, 2010Applicant: Synta Pharmaceuticals CorporationInventors: Mitsunori Ono, Lijun Sun, Yumiko Wada, Teresa Przewloka, Hao Li, Howard P. Ng, Zachary Demko
-
Patent number: 7750042Abstract: One embodiment of the present invention is a compound represented by the Structural Formula (I): Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.Type: GrantFiled: March 20, 2008Date of Patent: July 6, 2010Assignee: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono, Zhi-Qiang Xia
-
Publication number: 20100120722Abstract: This invention relates to pyrimidine compounds of formula (I), formula (I?), and formula (I?): and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, R5, U, V, W, X, Y, Z, and n are defined herein. This invention also relates to compositions comprising these compounds and methods for using them. The compounds and compositions of this invention are useful to treat or prevent disorders associated with excessive bone loss, including, without limitation periodontal disease, non-malignant bone disorders (such as osteoporosis, Pagers-disease of bone, osteogenesis imperfecta, fibrous dysplasia, and primary hyperparathyroidism) estrogen deficiency, inflammatory bone loss, bone malignancy, arthritis, osteopetrosis, and certain cancer-related disorders (such as hypercalcemia of malignancy (HCM), osteolytic bone lesions of multiple myeloma and osteolytic bone metastases of breast cancer and other metastatic cancers).Type: ApplicationFiled: January 15, 2010Publication date: May 13, 2010Applicant: Synta Pharmaceuticals Corp.Inventors: Mitsunori Ono, Lijun Sun, Yumiko Wada, Keizo Koya, Masazumi Nagai
-
Patent number: 7705029Abstract: What is claimed is a compound represented by the following structural formula: or a pharmaceutically acceptable salt, solvate or clathrate thereof. The variables for Structural Formula (I) are as described herein.Type: GrantFiled: April 5, 2007Date of Patent: April 27, 2010Assignee: Synta Pharmaceuticals Corp.Inventors: Shoujun Chen, Weiwen Ying, Jun Jiang, Mitsunori Ono, Lijun Sun
-
Patent number: 7687498Abstract: This invention features compounds of formula (I): pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12-related diseases and disorders.Type: GrantFiled: March 3, 2008Date of Patent: March 30, 2010Assignee: Synta Pharmaceuticals CorporationInventors: Mitsunori Ono, Lijun Sun, Yumiko Wada, Teresa Przewloka, Hao Li, Howard P. Ng, Zachary Demko
-
Publication number: 20100075015Abstract: This invention relates to a method of preparing an alpha acid-enriched hop composition that contains a low level of beta acids.Type: ApplicationFiled: May 19, 2009Publication date: March 25, 2010Applicant: Betal, LLCInventors: Mitsunori Ono, Naoto Yamaguchi
-
Patent number: 7671092Abstract: Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ?O or ?S.Type: GrantFiled: January 18, 2008Date of Patent: March 2, 2010Assignee: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono
-
Patent number: 7652168Abstract: Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): The thiohydrazide product compound is represented by Structural Formula (II): In Structural Formulas (I)-(II), R1 and R2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R2 is an aryl group or a substituted aryl group, then R5 is a hydrazine protecting group; and when R2 is an aliphatic or substituted aliphatic group, then R5 is —H or a hydrazine protecting group. R10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.Type: GrantFiled: August 29, 2008Date of Patent: January 26, 2010Assignee: Synta Pharmaceuticals Corp.Inventors: Shoujun Chen, Lijun Sun, Zhi-Qiang Xia, Keizo Kova, Mitsunori Ono
-
Publication number: 20090286884Abstract: The invention relates to compositions and processes for reducing the level of blood glucose or ameliorating diabetic symptoms in a subject by treatment with the composition which includes one or more safe and suitable hops acids or hops acid derivatives. More specifically, the process comprises using an ingredient or applying to a food or a nonfood product a composition-comprising beta hops acids in order to reduce blood glucose levels in Type 2 diabetics or its related diseases.Type: ApplicationFiled: February 17, 2009Publication date: November 19, 2009Inventors: Mitsunori Ono, John Paul Maye
-
Patent number: 7615552Abstract: This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.Type: GrantFiled: November 10, 2004Date of Patent: November 10, 2009Assignee: Synta Pharmaceuticals Corp.Inventors: Mitsunori Ono, Lijun Sun, Yumiko Wada, Teresa Przewloka, Hao Li, Zachary Demko, Dinesh Chimmanamada
-
Publication number: 20090258094Abstract: A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for treating various diseases, e.g., skin disorders, and bacterial infection.Type: ApplicationFiled: April 10, 2009Publication date: October 15, 2009Applicant: Flaxan GmbH & Co. KGInventors: Mitsunori Ono, Naoto Yamaguchi, Keiko Yamaguchi
-
Publication number: 20090253694Abstract: This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.Type: ApplicationFiled: February 20, 2009Publication date: October 8, 2009Applicant: Synta Pharmaceuticals Corp.Inventors: Mitsunori Ono, Lijun Sun, Yumiko Wada, Teresa Przewloka, Hao Li, Zachary Demko, Dinesh Chimmanamada
-
Patent number: 7569239Abstract: This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, folate, epigallocatechin gallate, epicatechin, epicatechin gallate, epigallocatechin, and polypheron E.Type: GrantFiled: May 6, 2005Date of Patent: August 4, 2009Assignee: The FRS CompanyInventors: Thomas Christian Lines, Mitsunori Ono
-
Publication number: 20090124703Abstract: A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for treating various diseases, e.g., skin disorders, and bacterial infection.Type: ApplicationFiled: August 13, 2008Publication date: May 14, 2009Applicant: Flaxan LLC.Inventors: Mitsunori Ono, Naoto Yamaguchi
-
Publication number: 20090092735Abstract: This invention features a method of making hop powder containing stable alkaline salts of hop bitter acids and an edible carrier. Also within the scope of this invention is a hop product containing alkaline salts of hop bitter acids and an edible carrier.Type: ApplicationFiled: October 5, 2007Publication date: April 9, 2009Applicant: Betal, LLCInventors: Naoto Yamaguchi, Mitsunori Ono
-
Publication number: 20090005594Abstract: Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): The thiohydrazide product compound is represented by Structural Formula (II): In Structural Formulas (I)-(II), R1 and R2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R2 is an aryl group or a substituted aryl group, then R5 is a hydrazine protecting group; and when R2 is an aliphatic or substituted aliphatic group, then R5 is —H or a hydrazine protecting group. R10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.Type: ApplicationFiled: August 29, 2008Publication date: January 1, 2009Inventors: Shoujun Chen, Lijun Sun, Zhi-Qiang Xia, Keizo Kova, Mitsunori Ono